[
  {
    "ts": null,
    "headline": "International Flavors & Fragrances Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "International Flavors & Fragrances Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=48ac28180e30d3f7b27955fe3c2d2140f228129b7ddcab0cbabd231853027f6c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749661680,
      "headline": "International Flavors & Fragrances Inc. stock underperforms Wednesday when compared to competitors",
      "id": 135254196,
      "image": "",
      "related": "IFF",
      "source": "MarketWatch",
      "summary": "International Flavors & Fragrances Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=48ac28180e30d3f7b27955fe3c2d2140f228129b7ddcab0cbabd231853027f6c"
    }
  },
  {
    "ts": null,
    "headline": "UBS Maintains Neutral Rating on International Flavors & Fragrances Inc. (IFF), PT $83",
    "summary": "International Flavors & Fragrances Inc. (NYSE:IFF) is one of the best wide moat stocks to buy now. On June 9, UBS analyst Joshua Spector reiterated a Neutral rating on IFF, with a consistent target price of $83. The analyst’s evaluation refers to the company’s latest Pharma divestment, which has successfully lowered its net debt-to-EBITDA ratio […]",
    "url": "https://finnhub.io/api/news?id=57cde47243504bff5ecd14cc2bb9ec2f92573c024a1b771c723f00294c96be54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749655852,
      "headline": "UBS Maintains Neutral Rating on International Flavors & Fragrances Inc. (IFF), PT $83",
      "id": 135191862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IFF",
      "source": "Yahoo",
      "summary": "International Flavors & Fragrances Inc. (NYSE:IFF) is one of the best wide moat stocks to buy now. On June 9, UBS analyst Joshua Spector reiterated a Neutral rating on IFF, with a consistent target price of $83. The analyst’s evaluation refers to the company’s latest Pharma divestment, which has successfully lowered its net debt-to-EBITDA ratio […]",
      "url": "https://finnhub.io/api/news?id=57cde47243504bff5ecd14cc2bb9ec2f92573c024a1b771c723f00294c96be54"
    }
  }
]